Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs PAGSEG Inc (PAGS) Price & Performance

Gilead Sciences, Inc.Trade
PAGSEG IncTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs PAGSEG Inc — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while PAGSEG Inc trades at $8.7 (market cap $2.48B). The key difference: Gilead Sciences, Inc. is far larger — about 67.9× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.7%). Which is the better fit depends on your goals.

GILDPAGS
Market Cap
$168.35B$2.48B
Sector
HealthTechnology
52-Week High
$155.80$12.00
52-Week Low
$110.56$8.38
Enterprise Value
$191.42B$10.22B
Dividend Yield
2.42%11.7%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.

The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.

PAGSEG Inc

PAGS trades at $8.72, down 3.96% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The stock presents compelling value with a P/E of 6.17 and P/B of 0.87, supported by strong profitability metrics including 53.05% gross margin and 14.52% ROE. Recent Q2 2026 earnings beat expectations with EPS of $0.41 versus $0.389 expected, while Q1 2026 showed a slight miss.

Analyst consensus remains bullish with 62.5% buy ratings and a $11.45 price target, suggesting 31% upside potential. Key risks include competitive pressures in Brazil's digital banking sector and macroeconomic sensitivity to interest rate cycles. The company maintains solid cash flow generation with $7.56B operating cash flow in 2025, supporting ongoing business expansion.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About PAGSEG Inc

PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.

Read more on PAGS